GLP1R and chronic kidney disease: GLP-1 RAs did not lead to significantly lower cardiovascular endpoints in patients with T2DM and CKD (eGFR < 60 mL/min/1.73 m2) (RR: 0.91; 95% CI: 0.80–1.04)